Financials

Financials in One Page

Hindustan Unilever is a ₹64,468 Cr (FY2026) FMCG cash machine: ~95% of sales in India, low-teens revenue CAGR over the last five years, operating margin in a 23-25% band, and free cash flow that lands at 14-16% of sales every year. The balance sheet carries virtually no net debt (₹1,478 Cr of borrowings against ₹4,359 Cr of investments plus liquid current assets), but it changed shape forever in FY2021 when the GSK Consumer Healthcare (Horlicks/Boost) merger added ~₹45,000 Cr of goodwill and intangibles, collapsing ROCE from triple digits (>100%) to a still-attractive ~28%. The market pays a Nifty-FMCG-style multiple — trailing P/E in the high-30s, sector premium of ~10-15% to itself in 2019, but a discount to Nestle India and Britannia. The single financial metric that matters most right now: underlying volume growth (UVG), which has hovered at 1-3% for three years and is the gating variable for any re-rating.

Reader's note on terms. Operating margin = operating profit ÷ revenue. ROCE (Return on Capital Employed) = EBIT ÷ (debt + equity); how many rupees of operating profit each rupee of invested capital generates. FCF margin = free cash flow ÷ revenue; how much of every rupee of sales drops to cash after running and re-investing in the business. Cash conversion cycle in days: positive means the company funds its working capital; negative means suppliers fund it. HUL's –79 days means vendors and trade credit finance the business — a structural FMCG strength.

Revenue, Margins, and Earnings Power

Revenue compounded at roughly 8.1% CAGR over FY2015-FY2026 in nominal INR — modest by Indian FMCG standards, dragged in FY2024-26 by single-digit volume growth and category mix headwinds in foods. The operating margin tells the better story: a 600 bps structural lift from 17% in FY2015 to a 23-25% steady-state today, driven by the premiumisation push (Dove, Tresemmé, Lakmé, Indulekha, Minimalist) and the savings programme that HUL calls "Net Productivity Programmes". This is what underwrites the franchise: revenue grows in line with India's nominal consumption, but margin is what compounds shareholder economics.

The FY2026 net margin of 23.4% is not the run-rate — it reflects a ~₹4,800 Cr one-off "other income" in Q3 FY26 tied to the Kwality Wall's ice cream demerger. Strip it out and underlying net margin lands near 17%, which is right on the four-year trend. The honest read on FY2026 earnings is that operating profit is essentially flat year-on-year: ₹15,039 Cr vs ₹14,843 Cr (+1.3%). For a stock trading at 36-49x earnings, that is the problem the market is wrestling with.

Recent quarterly trajectory

Revenue prints have been range-bound at ₹15,000-16,500 Cr per quarter for thirteen quarters, with sequential growth coming entirely from price/mix rather than volume. Operating margin has been a remarkably tight 23-24% band — management is defending margin through cost productivity and disciplined ad-spend, but at the cost of share losses in some discretionary categories. The ₹16,500 Cr Q1 FY26 print was an early signal of mix-led acceleration; Q2-Q4 settled back to the prior trend. The earnings-power judgment: HUL has stopped compounding profit and started defending it. That can be reversed by a rural recovery, but it is not happening yet.

Cash Flow and Earnings Quality

Free cash flow (FCF) is what's left over after the company pays for everything to run the business AND its capital expenditure (factories, fleets, IT systems). If a company reports a profit but doesn't generate the matching cash, you investigate. If it generates more cash than profit, you celebrate — usually because working capital is a source of funds.

HUL converts earnings to cash at near-100% over a full cycle. Operating cash flow has tracked or exceeded net income in 9 of the last 12 years (the CFO/PAT ratio in the data table). Free cash flow is ~14-16% of revenue every year, with two exceptions: FY2020 (~17% — pandemic working-capital release) and FY2024 (~23% — unusual working-capital benefit and tax timing). This is what a clean FMCG cash profile looks like.

The FY2026 chart looks alarming — net income above CFO for the first time — but that is the non-cash demerger gain sitting in net income, not a deterioration in cash quality. The operating cash flow (₹10,999 Cr) and FCF (₹9,668 Cr) are clean. Adjusted net income, stripping the Q3 one-off, is roughly ₹10,500 Cr — right in line with cash.

Earnings-quality watchouts

Earnings-quality verdict: high. The only meaningful distortion is the FY2026 demerger gain, which sits cleanly above EBIT and is visible to anyone who looks. Working capital is a source of funds, capex is low and steady, and CFO/PAT has averaged 100% across a full cycle. The dividend payout of 96-119% in recent years (FY24-25) is not a stress signal — it reflects a deliberate choice to return surplus cash because HUL cannot reinvest it at attractive incremental returns inside an already-saturated India FMCG footprint.

Balance Sheet and Financial Resilience

The HUL balance sheet has three things the reader should understand: it changed shape in FY2021, it carries effectively zero debt, and it sits on a large pile of goodwill from the GSK Consumer Healthcare merger.

The step-change in net worth in FY2021 (from ₹8,229 Cr to ₹47,674 Cr) is the GSK Consumer Healthcare merger — HUL absorbed the Horlicks/Boost portfolio in an all-equity deal, expanding the share base by ~9% and adding ~₹45,000 Cr of goodwill and brand intangibles to the asset side. This is also why net worth has fallen in FY25 and FY26 despite profits: dividend payout above 100% is drawing the equity down, and the demerger of Kwality Wall's removes more equity.

Balance-sheet verdict: top-tier. This is a net-cash, AAA-rated, supplier-financed business with no maturity wall, no covenant exposure, and almost no interest expense beyond capitalised leases. The only real balance-sheet risk is the ₹45,000 Cr of goodwill from the GSK deal. If Horlicks/Boost growth stalls structurally — and the foods segment has been the weakest part of HUL — that goodwill becomes an impairment risk. Watch the goodwill note in the FY26 annual report.

Returns, Reinvestment, and Capital Allocation

Two ROCE regimes coexist on the same income statement.

Pre-merger HUL ran ROCE between 91% and 139% because the asset base was tiny (almost no goodwill, low capex, vendor-funded working capital). The GSK Consumer Healthcare merger imported ~₹45,000 Cr of capital onto the books in FY2021, and ROCE compressed to 25-28% — still excellent in absolute terms, still 2-3x the Indian cost of equity, but a structurally different number. The question for the next decade is incremental ROCE on the GSK assets and on the Minimalist (Jan 2025, ₹2,955 Cr) and other premium beauty deals: are these adding 25%+ ROCE deals or diluting the corporate average?

Capital allocation: a near-100% payout business

HUL is a return-of-capital story, not a reinvestment story. Capex runs ₹1,000-1,500 Cr a year (about 2% of revenue). Dividend payout averaged ~90% of profit over FY2018-FY2025 and spiked above 100% in FY21, FY25 (special dividend ₹19/sh on top of regular). The share count is essentially fixed at ~235 Cr shares (the only material change was the ~9% GSK merger issuance in FY2021). There is no buyback programme — Indian listed-MNC subsidiaries with strong parent control rarely buy back.

The implied judgment from management is: the Indian FMCG core is fully built out; cash that cannot earn 25%+ ROCE at the margin should go back to shareholders. The acquisitions (GSK Consumer in 2020, OZiva and Wellbeing Nutrition stakes in 2022-23, Minimalist in 2025) are bolt-on premium-beauty plays, not platform changes. So far they are too small to move the corporate ROCE meaningfully.

EPS has compounded at ~10% over FY2018-FY2025 (excluding the one-off-inflated FY2026). FCF per share has compounded at a similar pace but with more volatility because working-capital swings show up here directly. Per-share value creation is real but unspectacular — roughly mid-teens total return over a decade once you add the ~1.8% dividend yield.

Segment and Unit Economics

Segment-level financials are reported by HUL but not present in the structured data files for this analysis. From the FY2025 Annual Report disclosure:

The economics judgment from the segment mix is critical. Home Care (laundry, dishwash, cleaners) is 35% of revenue but only ~19% of EBIT — it is volume-rich, margin-light, and exposed to crude/palm input swings. Beauty & Wellbeing and Personal Care together generate ~56% of EBIT on ~41% of revenue — these are the high-margin HPC engines where Dove, Lakmé, Tresemmé, Pond's and the new premium-beauty acquisitions (Minimalist, OZiva) live. Foods (Horlicks, Boost, Knorr, Kissan, Hellmann's) is a clear margin laggard at ~16% EBIT share on 19% of revenue. The Q3 FY26 demerger of Kwality Wall's Ice Cream (~5% of revenue, lowest-margin segment) is structurally accretive to corporate margin.

The structural read: when investors talk about "premiumisation", they are saying — make the Beauty & Wellbeing + Personal Care mix bigger and the Home Care + Foods mix smaller. Management is doing exactly this through acquisitions (Minimalist, OZiva, Acne Squad) and SKU rationalisation. The market is pricing the optionality of this mix shift.

Valuation and Market Expectations

HUL trades at a trailing P/E of 36.2x (TTM, reported) or roughly 49x on absolute FY2026 EPS of ₹64 if you take the reported number — but ~46x on adjusted EPS of ~₹46. The honest base case multiple is in the 36-46x range, depending on whether you include or exclude the demerger gain.

Where the multiple sits in its own history

HUL has spent the last decade trading between roughly 45x and 75x trailing P/E, with the peak around late 2020 / 2021 when COVID rural demand spiked. Today's ~36-46x band is the bottom decile of HUL's own ten-year valuation history — the stock has de-rated meaningfully even as earnings power has held up. The de-rating reflects three things: (1) volume growth stuck at 1-3% vs the 5-7% the franchise used to deliver; (2) ROCE reset from triple digits to ~28%; and (3) competition from Reliance Consumer (Campa, Independence), D2C beauty disruptors, and Patanjali in mass-tier categories.

Analyst consensus and price targets (as of early May 2026)

Consensus from 37 brokers: 25 Buy, 10 Hold, 3 Sell. Average target ₹2,566, implying +12-14% upside from ₹2,278. The Sell-side is leaning bullish but the spread is wide — Jefferies/ICICI Sec/Citi see 20%+ upside (rural recovery + premiumisation re-rating); BofA/Motilal/Morgan Stanley call it fairly priced.

Simple bear/base/bull frame

Valuation verdict: fair-to-mildly-undervalued. This is not a "cheap" stock on an absolute basis — 36x for low-single-digit EPS growth is not cheap. But relative to HUL's own ten-year history (45-75x), relative to Nestle India (84x), Britannia (52x) and Marico (62x), and relative to the franchise quality (AAA, net cash, 28% ROCE, 100% cash conversion), the de-rating has overshot. The asymmetric trade is real if — and only if — volume growth recovers. Without a UVG inflection, the multiple just sits.

Peer Financial Comparison

The peer gap that matters. HUL is the largest pure-play FMCG by revenue (ITC is bigger but ~40% of EBIT is cigarettes). On operating margin it sits in the middle of the peer set — above Britannia/Marico/Dabur, in line with Nestle, well below ITC's cigarette-juiced 34%. On ROCE (28%) it screens worse than every food/HPC peer except Dabur and Godrej CP, because of the post-GSK goodwill base. On P/E it trades at the cheapest end of the premium FMCG cohort (only ITC is materially lower, and ITC's 18.6x reflects the cigarette ESG discount). Net cash, AAA, 22% ROE, 1.8% yield, 36x earnings — the relative pitch is "scale leader at a structural multiple discount, waiting on volume". Nestle and Britannia trade at premiums because they grow faster; ITC trades at a discount because of category risk; HUL sits in between with the largest scale and the slowest growth.

What to Watch in the Financials

What the financials confirm: HUL is a high-quality, low-leverage, cash-generative franchise with industry-leading scale and a defensible 23-25% operating margin. What they contradict: the "compounder" narrative implicit in a high-30s P/E — earnings growth has been low single digits for three years and ROCE has structurally reset lower since the GSK merger. What to watch first: Q1 FY27 underlying volume growth, when management will report whether the rural-recovery thesis (consumer slowdown easing, monsoon-driven demand, GST cuts) is showing up in actual case sales.

The first financial metric to watch is underlying volume growth (UVG) in Q1 FY27. Anything above 5% would meaningfully change the case for the multiple; anything stuck at 1-3% would justify continued de-rating toward a 30-32x trailing P/E.